Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Solid Tumor Malignancy × selinexor × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Multiple Myeloma 42 Leukemia, Myeloid, Acute 21 Recurrence 19 Lymphoma, Large B-Cell, Diffuse 10 Sarcoma 8 Neoplasms, Plasma Cell 5 Lymphoma 5 Glioblastoma 5 Neurofibrosarcoma 4 Neoplasms 4 Neoplasm Metastasis 4 Lymphoma, T-Cell, Peripheral 4 Lymphoma, Non-Hodgkin 4 Endometrial Neoplasms 4 Colorectal Neoplasms 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Ovarian Neoplasms 3 Myelodysplastic Syndromes 3 Melanoma 3 Lymphoma, B-Cell 3 Liposarcoma 3 Glioma 3 Carcinoma 3 Waldenstrom Macroglobulinemia 2 Thymoma 2 Sarcoma, Alveolar Soft Part 2 Rhabdoid Tumor 2 Primary Myelofibrosis 2 Lymphoma, T-Cell, Cutaneous 2 Lymphoma, Mantle-Cell 2

Interventions

selinexor 1 Irinotecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05177276 2022-01-04

Selinexor Combination Ph 1 Study

Hackensack Meridian Health

Phase 1/2 Withdrawn

Other solid neoplasm

Solid Tumor Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡